Research progress of renal damage in rheumatoid arthritis_West China Medical Journal

Authors：

CHEN Xing ^1,2 ,  WEI Meng ²

1. School of Clinical Medicine, Southwest Jiaotong University, Chengdu, Sichuan 610031, P. R. China;
2. Department of Nephrology and Rheumatology, General Hospital of Western Theater Command, Chengdu, Sichuan 610083, P. R. China;

Corresponding author：

WEI Meng, Email: weimengwm@sina.com

Keywords：

Rheumatoid arthritis; Extra-articular manifestation; Renal damage

DOI：

10.7507/1002-0179.201906137

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Rheumatoid arthritis (RA) is one of the most common chronic inflammatory diseases. It mainly involves joints, as well as extra-articular organs. The extra-articular manifestations (EAM) are more common in patients with severe active disease, and the mortality of RA patients with EAM is 2.5 times of RA patients without EAM. Renal damage is rare in EAM, which mainly includes renal damage associated with RA itself, renal amyloidosis, and drug-induced secondary renal damage. In recent years, researches on RA renal damage have gradually increased, and mainly focused on therapy and prognosis. The recent research progress of RA renal damage are summarized in this review.

Citation： CHEN Xing, WEI Meng. Research progress of renal damage in rheumatoid arthritis. West China Medical Journal, 2019, 34(11): 1311-1314. doi: 10.7507/1002-0179.201906137 Copy

1.	Das S, Padhan P. An Overview of the extraarticular involvement in rheumatoid arthritis and its management. J Pharmacol Pharmacother, 2017, 8(3): 81-86.
2.	Cojocaru M, Cojocaru IM, Silosi I, et al. Extra-articular manifestations in rheumatoid arthritis. Maedica (Buchar), 2010, 5(4): 286-291.
3.	Turesson C. Extra-articular rheumatoid arthritis. Curr Opin Rheumatol, 2013, 25(3): 360-366.
4.	曾彩虹, 刘志红, 胡伟新, 等. 类风湿性关节炎相关肾损害的临床病理特征. 肾脏病与透析肾移植杂志, 2008, 17(4): 311-317.
5.	郭嘉隆, 章来晓. 系膜增生性肾小球肾炎. 中国社区医师, 2003, 19(9): 15-16.
6.	游雪叶, 钟山. 710 例肾脏穿刺活检病理与临床资料分析. 中国卫生标准管理, 2017, 8(24): 126-128.
7.	祖二梅, 闫桂霞, 刘新华. 泼尼松与吗替麦考酚酯治疗系膜增生性 IgA 肾小球肾炎患者的综合干预护理分析. 安徽医药, 2018, 22(6): 1186-1190.
8.	李宁, 林源. 贝那普利对系膜增生性肾小球肾炎大鼠血清和肾脏中 MMP-9/TIMP-1 的影响. 临床和实验医学杂志, 2018, 17(19): 2041-2043.
9.	徐峰, 曾彩虹. 类风湿性关节炎合并膜性肾病和节段坏死性病变. 肾脏病与透析肾移植杂志, 2014, 23(2): 192-196.
10.	Pozdzik A, Brochériou I, David C, et al. Membranous nephropathy and anti-podocytes antibodies: implications for the diagnostic workup and disease management. Biomed Res Int, 2018, 2018: 6281054.
11.	Li J, Liu B, Xue H, et al. miR-217 is a useful diagnostic biomarker and regulates human podocyte cells apoptosis via targeting TNFSF11 in membranous nephropathy. Biomed Res Int, 2017, 2017: 2168767.
12.	Shouno Y, Shimokama T, Sakemi T, et al. Segmental glomerular necrosis as an active index of IgA nephropathy: a study with 100 serial sections of 128 cases. Acta Pathol Jpn, 1993, 43(12): 723-729.
13.	于峰, 赵明辉, 于净, 等. 局灶节段坏死性肾小球肾炎 (FSNGN) 的临床和病理特点. 中国医刊, 2004, 39(4): 35-37.
14.	Stangou M, Papagianni A, Bantis C, et al. Detection of multiple cytokines in the urine of patients with focal necrotising glomerulonephritis may predict short and long term outcome of renal function. Cytokine, 2012, 57(1): 120-126.
15.	徐菲, 梁冰. 肾淀粉样变性的研究进展. 国际检验医学杂志, 2015, 36(8): 1126-1128.
16.	Courties A, Grateau G, Philippe P, et al. AA amyloidosis treated with tocilizumab: case series and updated literature review. Amyloid, 2015, 22(2): 84-92.
17.	Targońska-Stępniak B, Majdan M. Serum amyloid A as a marker of persistent inflammation and an indicator of cardiovascular and renal involvement in patients with rheumatoid arthritis. Mediators Inflamm, 2014, 2014: 793628.
18.	Burmester GR, Pope JE. Novel treatment strategies in rheumatoid arthritis. Lancet, 2017, 389(10086): 2338-2348.
19.	Sieper J, Poddubnyy D. Axial spondyloarthritis. Lancet, 2017, 390(10089): 73-84.
20.	Piga M, Chessa E, Ibba V, et al. Biologics-induced autoimmune renal disorders in chronic inflammatory rheumatic diseases: systematic literature review and analysis of a monocentric cohort. Autoimmun Rev, 2014, 13(8): 873-879.
21.	Stokes MB, Foster K, Markowitz GS, et al. Development of glomerulonephritis during anti-TNF-alpha therapy for rheumatoid arthritis. Nephrol Dial Transplant, 2005, 20(7): 1400-1406.
22.	Michel M, Henri P, Vincent FB, et al. Mesangial immunoglobulin (Ig)A glomerulonephritis in a patient with rheumatoid arthritis treated with abatacept. Joint Bone Spine, 2013, 80(6): 660-663.
23.	Matsuo Y, Mizoguchi F, Kohsaka H, et al. Tocilizumab-induced immune complex glomerulonephritis in a patient with rheumatoid arthritis. Rheumatology (Oxford), 2013, 52(7): 1341-1343.
24.	Kim SK, Choe JY. Gender is a risk factor for annual decline in estimated glomerular filtration rate in patients treated with biological DMARDs in rheumatoid arthritis and ankylosing spondylitis: a retrospective observational study. J Korean Med Sci, 2018, 33(30): e188.
25.	杜卉莲, 秦陆兵, 赵丽华, 等. 胱抑素 C 与尿微量白蛋白肌酐比值对早期继发性肾损害的临床研究. 中国地方病防治杂志, 2014, 29(增刊2): 109.
26.	韩智杰. 胱抑素 C 在类风湿关节炎中的变化及意义. 临床合理用药杂志, 2016, 9(7): 22-23.
27.	张玉军. 继发性肾损害的分子机制及防治药物的研究进展. 中国医院药学杂志, 2013, 33(17): 1431-1434.
28.	Turesson C, Schaid DJ, Weyand CM, et al. The impact of HLA-DRB1 genes on extra-articular disease manifestations in rheumatoid arthritis. Arthritis Res Ther, 2005, 7(6): R1386-R1393.
29.	Pawlik A, Paradowska-Gorycka A, Safranow K, et al. SLC22A5 polymorphism associated with risk of extra-articular manifestations in rheumatoid arthritis patients. Reumatologia, 2019, 57(1): 3-7.

1. Das S, Padhan P. An Overview of the extraarticular involvement in rheumatoid arthritis and its management. J Pharmacol Pharmacother, 2017, 8(3): 81-86.
2. Cojocaru M, Cojocaru IM, Silosi I, et al. Extra-articular manifestations in rheumatoid arthritis. Maedica (Buchar), 2010, 5(4): 286-291.
3. Turesson C. Extra-articular rheumatoid arthritis. Curr Opin Rheumatol, 2013, 25(3): 360-366.
4. 曾彩虹, 刘志红, 胡伟新, 等. 类风湿性关节炎相关肾损害的临床病理特征. 肾脏病与透析肾移植杂志, 2008, 17(4): 311-317.
5. 郭嘉隆, 章来晓. 系膜增生性肾小球肾炎. 中国社区医师, 2003, 19(9): 15-16.
6. 游雪叶, 钟山. 710 例肾脏穿刺活检病理与临床资料分析. 中国卫生标准管理, 2017, 8(24): 126-128.
7. 祖二梅, 闫桂霞, 刘新华. 泼尼松与吗替麦考酚酯治疗系膜增生性 IgA 肾小球肾炎患者的综合干预护理分析. 安徽医药, 2018, 22(6): 1186-1190.
8. 李宁, 林源. 贝那普利对系膜增生性肾小球肾炎大鼠血清和肾脏中 MMP-9/TIMP-1 的影响. 临床和实验医学杂志, 2018, 17(19): 2041-2043.
9. 徐峰, 曾彩虹. 类风湿性关节炎合并膜性肾病和节段坏死性病变. 肾脏病与透析肾移植杂志, 2014, 23(2): 192-196.
10. Pozdzik A, Brochériou I, David C, et al. Membranous nephropathy and anti-podocytes antibodies: implications for the diagnostic workup and disease management. Biomed Res Int, 2018, 2018: 6281054.
11. Li J, Liu B, Xue H, et al. miR-217 is a useful diagnostic biomarker and regulates human podocyte cells apoptosis via targeting TNFSF11 in membranous nephropathy. Biomed Res Int, 2017, 2017: 2168767.
12. Shouno Y, Shimokama T, Sakemi T, et al. Segmental glomerular necrosis as an active index of IgA nephropathy: a study with 100 serial sections of 128 cases. Acta Pathol Jpn, 1993, 43(12): 723-729.
13. 于峰, 赵明辉, 于净, 等. 局灶节段坏死性肾小球肾炎 (FSNGN) 的临床和病理特点. 中国医刊, 2004, 39(4): 35-37.
14. Stangou M, Papagianni A, Bantis C, et al. Detection of multiple cytokines in the urine of patients with focal necrotising glomerulonephritis may predict short and long term outcome of renal function. Cytokine, 2012, 57(1): 120-126.
15. 徐菲, 梁冰. 肾淀粉样变性的研究进展. 国际检验医学杂志, 2015, 36(8): 1126-1128.
16. Courties A, Grateau G, Philippe P, et al. AA amyloidosis treated with tocilizumab: case series and updated literature review. Amyloid, 2015, 22(2): 84-92.
17. Targońska-Stępniak B, Majdan M. Serum amyloid A as a marker of persistent inflammation and an indicator of cardiovascular and renal involvement in patients with rheumatoid arthritis. Mediators Inflamm, 2014, 2014: 793628.
18. Burmester GR, Pope JE. Novel treatment strategies in rheumatoid arthritis. Lancet, 2017, 389(10086): 2338-2348.
19. Sieper J, Poddubnyy D. Axial spondyloarthritis. Lancet, 2017, 390(10089): 73-84.
20. Piga M, Chessa E, Ibba V, et al. Biologics-induced autoimmune renal disorders in chronic inflammatory rheumatic diseases: systematic literature review and analysis of a monocentric cohort. Autoimmun Rev, 2014, 13(8): 873-879.
21. Stokes MB, Foster K, Markowitz GS, et al. Development of glomerulonephritis during anti-TNF-alpha therapy for rheumatoid arthritis. Nephrol Dial Transplant, 2005, 20(7): 1400-1406.
22. Michel M, Henri P, Vincent FB, et al. Mesangial immunoglobulin (Ig)A glomerulonephritis in a patient with rheumatoid arthritis treated with abatacept. Joint Bone Spine, 2013, 80(6): 660-663.
23. Matsuo Y, Mizoguchi F, Kohsaka H, et al. Tocilizumab-induced immune complex glomerulonephritis in a patient with rheumatoid arthritis. Rheumatology (Oxford), 2013, 52(7): 1341-1343.
24. Kim SK, Choe JY. Gender is a risk factor for annual decline in estimated glomerular filtration rate in patients treated with biological DMARDs in rheumatoid arthritis and ankylosing spondylitis: a retrospective observational study. J Korean Med Sci, 2018, 33(30): e188.
25. 杜卉莲, 秦陆兵, 赵丽华, 等. 胱抑素 C 与尿微量白蛋白肌酐比值对早期继发性肾损害的临床研究. 中国地方病防治杂志, 2014, 29(增刊2): 109.
26. 韩智杰. 胱抑素 C 在类风湿关节炎中的变化及意义. 临床合理用药杂志, 2016, 9(7): 22-23.
27. 张玉军. 继发性肾损害的分子机制及防治药物的研究进展. 中国医院药学杂志, 2013, 33(17): 1431-1434.
28. Turesson C, Schaid DJ, Weyand CM, et al. The impact of HLA-DRB1 genes on extra-articular disease manifestations in rheumatoid arthritis. Arthritis Res Ther, 2005, 7(6): R1386-R1393.
29. Pawlik A, Paradowska-Gorycka A, Safranow K, et al. SLC22A5 polymorphism associated with risk of extra-articular manifestations in rheumatoid arthritis patients. Reumatologia, 2019, 57(1): 3-7.

Previous Article
Analysis of long-term effect on cardiopulmonary resuscitation skills in medical students with different training methods
Next Article
Progress in research on pusher syndrome

West China Medical Journal

Research progress of renal damage in rheumatoid arthritis

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content